Skip to main content
Top
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | NSCLC | Research

Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings

Authors: Atsushi Kagimoto, Takeshi Mimura, Atsushi Kamigaichi, Yoshinori Yamashita

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

The prognosis of patients with lung cancer who demonstrate pleural plaques intraoperatively, which may be associated with exposure to asbestos, is unclear. Here, we compared the clinicopathological characteristics and prognosis of these patients to those of patients without pleural plaques.

Methods

We included patients who underwent curative-intent resection for non-small cell lung cancer. We retrospectively investigated the relationship of intrathoracic findings of pleural plaques with clinicopathological features and prognosis.

Results

Pleural plaques were found in 121/701 patients (17.3%) during surgery. The incidence of squamous cell carcinoma (P < 0.001) and the pathological stage (P = 0.021) were higher in patients with pleural plaques. Overall survival was significantly worse in patients with pleural plaques (5-year rate; 64.5% vs. 79.3%; P < 0.001), and the same finding was noted in clinical stage I patients (5-year rate; 64.8% vs. 83.4%; P < 0.001). In multivariable analysis, the presence of pleural plaques was a significant predictor of overall survival in patients with clinical stage I (hazard ratio, 1.643; P = 0.036). In the analysis among patients with emphysema more severe than Goddard score 5 points or interstitial pneumonia, overall survival was significantly worse in those with pleural plaques than in those without pleural plaques (5-year rate; 66.3% vs. 49.5%; P < 0.001).

Conclusions

Patients with non-small cell lung cancer who underwent resection and demonstrated pleural plaques intraoperatively had a significantly worse prognosis. It is important to recognize the presence of pleural plaques intraoperatively, and our findings will be useful in determining the treatment and follow-up strategy for such patients with lung cancer and pleural plaques on intrathoracic examination.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brims FJH, Kong K, Harris EJA, Sodhi-Berry N, Reid A, Murray CP, et al. Pleural plaques and the risk of lung cancer in asbestos-exposed subjects. Am J Respir Crit Care Med. 2020;201:57–62.CrossRef Brims FJH, Kong K, Harris EJA, Sodhi-Berry N, Reid A, Murray CP, et al. Pleural plaques and the risk of lung cancer in asbestos-exposed subjects. Am J Respir Crit Care Med. 2020;201:57–62.CrossRef
2.
go back to reference Koskinen K, Zitting A, Tossavainen A, Rinne JP, Roto P, Kivekäs J, et al. Radiographic abnormalities among Finnish construction, shipyard and asbestos industry workers. Scand J Work Environ Health. 1998;24:109–17.CrossRef Koskinen K, Zitting A, Tossavainen A, Rinne JP, Roto P, Kivekäs J, et al. Radiographic abnormalities among Finnish construction, shipyard and asbestos industry workers. Scand J Work Environ Health. 1998;24:109–17.CrossRef
3.
go back to reference Hasleton P, Galateau-Salle F, King J, Rossi G, Lantuejoul S, Preston R, et al. Diseases of the pleura. In: Hasleton P, Flieder DB, editors., et al., Spencer’s pathology of the lung. 6th ed. Cambridge: Cambridge University Press; 2013. p. 1437–43.CrossRef Hasleton P, Galateau-Salle F, King J, Rossi G, Lantuejoul S, Preston R, et al. Diseases of the pleura. In: Hasleton P, Flieder DB, editors., et al., Spencer’s pathology of the lung. 6th ed. Cambridge: Cambridge University Press; 2013. p. 1437–43.CrossRef
4.
go back to reference Woodard PK, McAdams HP, Putman CE. Asbestos exposure and asbestosis: clarifying terminology and avoiding confusion. J R Soc Med. 1995;88:669–71.PubMedPubMedCentral Woodard PK, McAdams HP, Putman CE. Asbestos exposure and asbestosis: clarifying terminology and avoiding confusion. J R Soc Med. 1995;88:669–71.PubMedPubMedCentral
5.
go back to reference Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.PubMedPubMedCentral Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.PubMedPubMedCentral
8.
go back to reference Kishimoto T, Gemba K, Fujimoto N, Onishi K, Usami I, Mizuhashi K, et al. Clinical study of asbestos-related lung cancer in Japan with special reference to occupational history. Cancer Sci. 2010;101:1194–8.CrossRef Kishimoto T, Gemba K, Fujimoto N, Onishi K, Usami I, Mizuhashi K, et al. Clinical study of asbestos-related lung cancer in Japan with special reference to occupational history. Cancer Sci. 2010;101:1194–8.CrossRef
9.
go back to reference Tamura A, Funakoshi M, J-p NA, Hasegawa K, Ishimine A, Koike A, et al. Potential asbestos exposure among patients with primary lung cancer in Japan. J Occup Health. 2018;60:236–45.CrossRef Tamura A, Funakoshi M, J-p NA, Hasegawa K, Ishimine A, Koike A, et al. Potential asbestos exposure among patients with primary lung cancer in Japan. J Occup Health. 2018;60:236–45.CrossRef
10.
go back to reference Nishi H, Washio K, Fujimoto N, Gemba K, Kishimoto T, Shimizu N, et al. Evaluation of asbestos-related lung cancer. JJLC. 2009;49:167–73 ((in Japanese)).CrossRef Nishi H, Washio K, Fujimoto N, Gemba K, Kishimoto T, Shimizu N, et al. Evaluation of asbestos-related lung cancer. JJLC. 2009;49:167–73 ((in Japanese)).CrossRef
11.
go back to reference Hillerdal G. The pathogenesis of pleural plaques and pulmonary asbestosis: possibilities and impossibilities. Eur J Respir Dis. 1980;61:129–38.PubMed Hillerdal G. The pathogenesis of pleural plaques and pulmonary asbestosis: possibilities and impossibilities. Eur J Respir Dis. 1980;61:129–38.PubMed
12.
go back to reference Evans DC, Peattie MR. Kaigun: Strategy, Tactics, and Technology in the Imperial Japanese Navy. Annapolis: Naval Institute Press; 1997. p. 1887–941. Evans DC, Peattie MR. Kaigun: Strategy, Tactics, and Technology in the Imperial Japanese Navy. Annapolis: Naval Institute Press; 1997. p. 1887–941.
13.
go back to reference Suzuki K, Watanabe SI, Wakabayashi M, Saji H, Aokage K, Moriya Y, et al. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg. 2022;163:289-301.e2.CrossRef Suzuki K, Watanabe SI, Wakabayashi M, Saji H, Aokage K, Moriya Y, et al. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg. 2022;163:289-301.e2.CrossRef
14.
go back to reference Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRef Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRef
15.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRef Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRef
16.
go back to reference Kagimoto A, Mimura T, Miyamoto T, Nakashima C, Yamashita Y. Severity of emphysema as a prognosticator of resected early lung cancer: an analysis classified by Goddard score. Jpn J Clin Oncol. 2020;50:1043–50.CrossRef Kagimoto A, Mimura T, Miyamoto T, Nakashima C, Yamashita Y. Severity of emphysema as a prognosticator of resected early lung cancer: an analysis classified by Goddard score. Jpn J Clin Oncol. 2020;50:1043–50.CrossRef
17.
go back to reference Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRef Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRef
18.
go back to reference Pairon JC, Andujar P, Rinaldo M, Ameille J, Brochard P, Chamming’s S, et al. Asbestos exposure, pleural plaques, and the risk of death from lung cancer. Am J Respir Crit Care Med. 2014;190:1413–20.CrossRef Pairon JC, Andujar P, Rinaldo M, Ameille J, Brochard P, Chamming’s S, et al. Asbestos exposure, pleural plaques, and the risk of death from lung cancer. Am J Respir Crit Care Med. 2014;190:1413–20.CrossRef
19.
go back to reference Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39–45.PubMed Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39–45.PubMed
20.
go back to reference Jiang L, Nagai H, Ohara H, Hara S, Tachibana M, Hirano S, et al. Characteristics and modifying factors of asbestos-induced oxidative DNA damage. Cancer Sci. 2008;99:2142–51.CrossRef Jiang L, Nagai H, Ohara H, Hara S, Tachibana M, Hirano S, et al. Characteristics and modifying factors of asbestos-induced oxidative DNA damage. Cancer Sci. 2008;99:2142–51.CrossRef
21.
go back to reference Yu S, Choi HH, Kim IW, Kim TJ. Conditioned medium from asbestos-exposed fibroblasts affects proliferation and invasion of lung cancer cell lines. PLoS ONE. 2019;14:e0222160.CrossRef Yu S, Choi HH, Kim IW, Kim TJ. Conditioned medium from asbestos-exposed fibroblasts affects proliferation and invasion of lung cancer cell lines. PLoS ONE. 2019;14:e0222160.CrossRef
22.
go back to reference Churg A. Fiber counting and analysis in the diagnosis of asbestos-related disease. Hum Pathol. 1982;13:381–92.CrossRef Churg A. Fiber counting and analysis in the diagnosis of asbestos-related disease. Hum Pathol. 1982;13:381–92.CrossRef
23.
go back to reference Kopylev L, Christensen KY, Brown JS, Cooper GS. A systematic review of the association between pleural plaques and changes in lung function. Occup Environ Med. 2015;72:606–14.CrossRef Kopylev L, Christensen KY, Brown JS, Cooper GS. A systematic review of the association between pleural plaques and changes in lung function. Occup Environ Med. 2015;72:606–14.CrossRef
24.
go back to reference Tsutani Y, Mimura T, Kai Y, Ito M, Misumi K, Miyata Y, et al. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. J Thorac Cardiovasc Surg. 2017;154:1089-1096.e1.CrossRef Tsutani Y, Mimura T, Kai Y, Ito M, Misumi K, Miyata Y, et al. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. J Thorac Cardiovasc Surg. 2017;154:1089-1096.e1.CrossRef
Metadata
Title
Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings
Authors
Atsushi Kagimoto
Takeshi Mimura
Atsushi Kamigaichi
Yoshinori Yamashita
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-09600-6

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine